Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial

VIENNA — Results from the phase 3 SELECT-GCA study showed that the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) induces significant and sustained remission in people with new-onset or relapsing giant cell arteritis (GCA). The primary endpoint of sustained remission — the absence of GCA signs or symptoms from weeks 12 to 52 together with adherence ...

https://teach.coursemateai.com/home/course/get-it-done/163 
Get In Touch

Cape Breton, NS

+012 345 67890

Chris@websurfer.ca

Follow Us
Flickr Photos

Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved